Atorvastatin: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
|||
(14 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | |||
{{CMG | |||
===[[Atorvastatin calcium]] ([[Atorvastatin calcium|Lipitor]])=== | |||
===[[Amlodipine besylate/Atorvastatin calcium]]=== | |||
===[[Amlodipine/Atorvastatin]]=== | |||
===[[Ezetimibe/Atorvastatin]]=== | |||
==Overview== | ==Overview== | ||
Atorvastatin is a | Atorvastatin is a HMG-COA Reductase Inhibitor drug that is FDA approved for the treatment of hyperlipidemia, prevention of cardiovascular disease. Adverse reactions include [[diarrhea]], [[arthralgia]], [[myalgia]], urinary tract infectious disease, [[nasopharyngitis]], pain, in extremity. | ||
==Category== | ==Category== | ||
HMG-COA Reductase Inhibitor | |||
Latest revision as of 14:27, 24 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Atorvastatin calcium (Lipitor)
Amlodipine besylate/Atorvastatin calcium
Amlodipine/Atorvastatin
Ezetimibe/Atorvastatin
Overview
Atorvastatin is a HMG-COA Reductase Inhibitor drug that is FDA approved for the treatment of hyperlipidemia, prevention of cardiovascular disease. Adverse reactions include diarrhea, arthralgia, myalgia, urinary tract infectious disease, nasopharyngitis, pain, in extremity.
Category
HMG-COA Reductase Inhibitor